PubMed Health⌕ Search

PubMed · 11008296

[Epilepsy and learning disorders].

Abstract

INTRODUCTION: Children with epilepsy have more behavioral and cognitive problem than children with other chronic illness and children in the general population. Risk factors are multiple probably involving a combination of seizure, family and child variable, behavioral problems (depression, occur frequently but may be unrecognized). Anxiety disorders and psychoses are less common. DEVELOPMENT: The learning and behavioral found in epileptic children is multifactorial, first the effects of the conditions causing the epilepsy, in addition the epilepsy itself may cause, change in the nervous system through the metabolic and excitatory effects of the seizure and the neurotransmitter elements involved at the membrane level. The effects of the treatment modality, be it pharmacology or surgical may also play havoc with cognition function. CONCLUSION: The neurobehavioral effects of antiepileptic drug although probably less important with the newer agent than in the past, must be considered especially in polypharmacy as recent report have in dictated.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Archila. [Epilepsy and learning disorders].. https://pubmed.ncbi.nlm.nih.gov/11008296/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗